CoCA kodulehekülg.

Psychiatric disorders are highly co-morbid, both with somatic and other mental disorders, and are one of the last areas of medicine where disease classifications are driven by phenomenology rather than pathophysiology. Here, we will study the comorbidity between the most frequent psychiatric conditions, attention-deficit/hyperactivity disorder (ADHD), mood and anxiety disorders, substance use disorders (SUD), and a highly prevalent somatic disorder, i.e. obesity. In this project, the CoCA consortium will:
• specify the population prevalence and sex-specificity of comorbidity of ADHD’s comorbidity with mood and anxiety disorders, SUD, and obesity across the lifespan (WP1)
• determine the socioeconomic impact of ADHD in conjunction with its common comorbid disorders (WP1)
• specify the genetic and environmental contributions to the overlap among the disorders (WP2)
• determine the biological mechanisms underlying ADHD and its comorbid disorders (mood and anxiety disorders, SUD, obesity) (WP2,3,4):
o Sleep and the circadian rhythm system (CIRCA system) (WP2,3)
o Reward processing system and dopaminergic neurotransmission therein (DA system) (WP2,4)
o Additional, currently unknown biological pathways derived from genetic big data studies (WP2)
• test biomarkers from candidate systems (CIRCA, DA) and identify novel ones (WP2,3,4)
• develop algorithms to predict the development of ADHD’s comorbidities based on epidemiological/genetic data as well as the CIRCA/DA systems (WP7)
• improve the diagnosis of ADHD-related comorbidity in adolescence / early adulthood through mobile healthcare (mHealth) approaches (WP5)
• develop an mHealth approach to support patients in daily life (mHealth-based monitoring and coaching) (WP5,6)
• establish effect sizes of non-pharmacologic treatments for ADHD with comorbid obesity and depression by targeting the CIRCA/DA systems with chronobiological approaches, physical exercise and mHealth-based coaching (WP6)
• explore targets for novel pharmacologic treatment strategies for ADHD and its comorbid disorders (WP8)
• disseminate results to the public, emphasizing the role of life-style modifications for prevention (WP9)
• educate and train a new generation of inter- and transdisciplinary researchers and clinicians (WP10)

Viimati lisatud